FLNA — Filana Therapeutics Share News
0.000.00%
Last trade - 00:00Cassava Sciences rises after US DOJ closes probe into company
Cassava Sciences says US DOJ has closed investigation into company
Brief: Cassava Announces Agreement To Settle Securities Class Action Litigation
Brief: Cassava Sciences Inc - On Dec 15, FDA Places Full Clinical Hold On Cassava's Trial - SEC Filing
Brief: Cassava Sciences Inc - FDA Requires Additional Information From Cassava For Clinical Study - SEC Filing
Brief: Cassava Sciences To Offer Securities Up To $200 Million
Cassava Sciences Q3 net loss narrows, beats expectations
Brief: Cassava Sciences Q3 Basic EPS USD -0.22
Brief: Cassava Sciences Appoints Dawn C. Bir to the Board of Directors
Brief: Cassava Sciences Q2 Basic EPS USD -0.92
Brief: Cassava Sciences Appoints Dr. Joseph Hulihan As Chief Medical Officer
Brief: Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam For Tsc-Related Epilepsy
Cassava Sciences must face malicious prosecution lawsuit over Alzheimer's drug
U.S. STOCKS ON THE MOVE-Affirm, Trump Media, Comstock
Cassava falls after failing in second late-stage trial
Cassava falls after stopping development of Alzheimer's drug
Cassava to discontinue development of Alzheimer's disease drug (updated)
Cassava to discontinue development of Alzheimer's disease drug
Brief: Cassava Sciences Provides A Business Update